Skip to content

The effect of taurine on embryo quality in elderly patients with diminished ovarian reserve: A randomized controlled study

The effect of taurine on embryo quality in elderly patients with diminished ovarian reserve: A randomized controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118126
Enrollment
Unknown
Registered
2026-02-02
Start date
2026-02-02
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

control group:The patient does not take any supplements other than folic acid.
Intervention group:Oral administration of taurine (3.2 g daily) is initiated on menstrual cycle days 2–3, one month prior to the start of the controlled ovarian stimulation cycle

Sponsors

Reproductive Medicine Center, the 901th Hospital of the Joint logistics support Force of People’s Liberation Army
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
35 Years to 43 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 35 to 43 who underwent IVF/ICSI-ET treatment due to infertility; 2. Meeting the criteria for Poseidon Group 4 of diminished ovarian reserve (AFC < 5, AMH < 1.2 ng/ml); 3. 18.5kg/m^2<=Body Mass Index (BMI)<28 kg/m^2; 4. Full understanding of the study content, voluntary participation, and provision of signed written informed consent.

Exclusion criteria

Exclusion criteria: 1.Those with uncontrollable medical diseases that may interfere with or affect the research results, such as serious liver, kidney, heart, brain diseases; 2.Taking other micronutrients, hormones or other drugs that affect fertility except folic acid within one month; 3.Diagnosis of uncontrolled endocrine or metabolic disorders (e.g., thyroid dysfunction, diabetes mellitus, hyperprolactinemia); 4.Known allergy or hypersensitivity to the investigational products (taurine, Coenzyme Q10) or their excipients; 5. Those who failed to return for follow-up appointments on time, had incomplete medical records, and were lost to follow-up for various reasons.

Design outcomes

Primary

MeasureTime frame
Number of day 3 high-quality embryos;

Secondary

MeasureTime frame
Number of oocytes retrieved ;Number of MII oocytes;Number of fertilized oocytes (2PN);Number of day 3 available embryos;anti-Müllerian hormone;Biochemical pregnancy;Clinical pregnancy;Early abortion;

Countries

China

Contacts

Public ContactSu Lin

the 901th Hospital of the Joint logistics support Force of People’s Liberation Army

731106451@qq.com+86 189 5518 9436

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026